2-Deoxyglucose Dendrimer-Enabled Niclosamide Delivery to FRβ-Expressing Macrophages Alleviates Endometriosis Progression and Associated Hyperalgesia

Anubhav Dhull, Dhull A, Mingxin Shi, Harvey ME, Madeleine E. Harvey, Taylor M Page, Sharma R, Rishi Sharma, Kenneth John Goody, Goody KJ, Aqib Iqbal Dar, Dar AI, Nash S. Moawad, Vijay Kumar Sirohi, Sirohi VK, Cooke PS, Paul S. Cooke, Kanako Hayashi, Anjali Anjali Sharma, Anjali Sharma
Advanced healthcare materials · 2026 · pp. e71661 · doi:10.1002/adhm.71661 · PMID:42670248 · W7128485652
article OA: hybrid public-domain-us
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-05 ⓘ

A niclosamide-loaded dendrimer targeted to folate receptor-β-positive macrophages reduced lesion burden and hyperalgesia in a mouse endometriosis model, demonstrating the therapeutic potential of this nonhormonal nanomedicine.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis (EuE) is a chronic, incurable disease. Due to limited efficacy, high recurrence rates, and serious side effects of current treatments, development of new, targeted, nonhormonal therapies is urgently needed. We previously reported that niclosamide, an FDA-approved anthelmintic drug, attenuates endometriotic lesion growth. We further identified folate receptor-β (FRβ)-positive macrophages as contributors to disease progression. Significantly, niclosamide inhibits FRβ+ macrophages and reduces inflammation, innervation, and angiogenesis. To develop niclosamide as a nonhormonal and selective immune cell-targeted therapy for EuE, we engineered a folic acid (FA)-conjugated 2-deoxyglucose dendrimer (FA-2DG-D) using click chemistry to enable selective FRβ-mediated uptake. Conjugation of niclosamide to FA-2DG-D yielded a targeted nanotherapeutic (FA-2DG-D-Niclo) with enhanced aqueous solubility, controlled intracellular release, and excellent batch-to-batch reproducibility. In a mouse model of EuE, FA-2DG-D demonstrated lesion-specific accumulation and selective internalization by FRβ+ macrophages with minimal off-target organ retention. A single intraperitoneal dose of FA-2DG-D-Niclo (25 or 50 mg/kg/bw of niclosamide) significantly reduced FRβ+ macrophage burden, suppressed lesion number and volume, and markedly improved EuE-associated hyperalgesia at 2 weeks post-treatment. Together, these findings establish FRβ+ macrophages as a potential target in EuE and present FA-2DG-D-Niclo as a nonhormonal, macrophage-focused nanomedicine for precise and effective endometriosis treatment.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (63)

SciLite annotations

chemicals 7
niclosamide niclosamide niclosamide niclosamide folic acid 2-hydroxymethylglutarate polycarbazole polymer
organisms 1
transgenic mice

Source provenance

europepmc
last seen: 2026-09-09T06:15:24.302764+00:00
openalex
last seen: 2026-09-02T06:04:46.041018+00:00
pubmed
last seen: 2026-09-09T06:08:42.484907+00:00
scilite
last seen: 2026-09-06T10:05:09.034756+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine